DH
Therapeutic Areas
Botanix Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sofdra™ (sofpironium) topical gel, 12.45% | Primary Axillary Hyperhidrosis (Excessive Underarm Sweating) | Approved |
| BTX 1503 | Acne (in adults and teenagers) | Clinical Development |
| BTX 1702 | Papulopustular Rosacea | Pre-clinical / Early Development |
| BTX 1204A | Atopic Dermatitis (Canine & Human potential) | Pilot Study |
| BTX 1801 | Staphylococcus Aureus / MRSA Decolonization (in Hemodialysis Patients) | Pre-clinical / Research |
Leadership Team at Botanix Pharmaceuticals
VI
Vince Ippolito
Executive Chairman
DS
Dr. Stewart Washer
Director
DB
Dr. Bill Bosch
Non-Executive Director
DS
Danny Sharp
Non-Executive Director
DP
Dr. Patricia Walker
Non-Executive Director
HC
Haley Chartres
Company Contact / Author